Platinum chromium stent system approved by FDACardiology TodayBoston Scientific announced that its next-generation everolimus-eluting platinum chromium coronary stent system was approved for the treatment of patients with coronary artery disease. The P…
Everolimus prolongs progression-free survival for patients with neuroendocrine …EurekAlert (press release)HOUSTON — Combination treatment with everolimus, an inhibitor of the mammalian target rapamycin (mTOR), and octreotide has shown to improve pro…
Invited CommentaryArchives of Internal MedicineAvailable treatments for AECOPDs include antibiotics, bronchodilators, noninvasive ventilation, and corticosteroids, 7 but, unfortunately, nearly all studies of ACEOPDs have excluded persons who are at the…
MD News (press release)Everolimus Ups Survival in Carcinoid SyndromeMD News (press release)For patients with low- or intermediate-grade advanced neuroendocrine tumors (carcinoids), everolimus plus octreotide long-acting repeatable (LAR) improves progre…
Low-Dose Corticosteroids for Treating Acute LaminitisTheHorse.comCorticosteroids, which veterinarians have historically advised against using to treat laminitic horses, might be one of those therapies warranting reconsideration. With this in mind, Robe…
MMF Found Superior for Lupus NephritisRenal and Urology NewsMycophenolate mofetil (MMF) is more effective than azathioprine as maintenance therapy for patients with active lupus nephritis (LN) who responded to induction therapy, researchers reported. I…
New Drug-Eluting Stent Wins FDA OkayMedPage TodayThe FDA has approved Promus Element Plus, a platinum-chromium coronary stent that elutes everolimus, manufacturer Boston Scientific announced. According to the company, the product uses a proprietary all…
Boston Receives FDA Approval for PROMUS Element™ PlusGalaxy StocksBoston Scientific Corporation has recently announced that it has won approval from US Food and Drug Administration (FDA) for the PROMUS Element™ Plus Everolimus-Eluting Platinum Chro…
Everolimus Slows Progression in Carcinoid TumorsMedPage TodayExplain that adding everolimus to a somatostatin analog led to improved progression-free survival among patients with advanced neuroendocrine tumors. Point out that benefits were seen in the …
WTNHPromus Element DES approved as longitudinal compression issue gains steamTheHeart.OrgRockville, MD and Detroit, MI – The US Food and Drug Administration (FDA) has approved the Promus Element Plus everolimus-eluting chromium platinum coronary stent …